Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes
Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and...
Gespeichert in:
Veröffentlicht in: | The Journal of immunology (1950) 2002-02, Vol.168 (3), p.1154-1166 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1166 |
---|---|
container_issue | 3 |
container_start_page | 1154 |
container_title | The Journal of immunology (1950) |
container_volume | 168 |
creator | Cippitelli, Marco Fionda, Cinzia Di Bona, Danilo Di Rosa, Francesca Lupo, Aldo Piccoli, Mario Frati, Luigi Santoni, Angela |
description | Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and for maintenance of peripheral tolerance. Aberrant expression of Fas and FasL has also been implicated in diseases in which the lymphocyte homeostasis is compromised, and several studies have described the pathogenic functions of Fas and FasL in vivo, particularly in the induction/regulation of organ-specific autoimmune diseases. The 1,25(OH)(2)D(3) is a secosteroid hormone that activates the nuclear receptor vitamin D(3) receptor (VDR), whose immunosuppressive activities have been well studied in different models of autoimmune disease and in experimental organ transplantation. We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-gamma and IL-12 genes by 1,25(OH)(2)D(3) in activated T lymphocytes and macrophages/dendritic cells. In this study, we describe the effect of 1,25(OH)(2)D(3) on the activation of the fasL gene in T lymphocytes. We show that 1,25(OH)(2)D(3) inhibits activation-induced cell death, fasL mRNA expression, and that 1,25(OH)(2)D(3)-activated VDR represses fasL promoter activity by a mechanism dependent on the presence of a functional VDR DNA-binding domain and ligand-dependent transcriptional activation domain (AF-2). Moreover, we identified a minimal region of the promoter containing the transcription start site and a noncanonical c-Myc-binding element, which mediates this repression. These results place FasL as a novel target for the immunoregulatory activities of 1,25(OH)(2)D(3), and confirm the interest for a possible pharmacological use of this molecule and its derivatives. |
doi_str_mv | 10.4049/jimmunol.168.3.1154 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71413599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71413599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-818fb3858cdfbbfe6e980dad6586a58b148f6b64e6f15d08f1d2d7889afe52f53</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EouXxBUjIK1ileJLYcZaoLQWpAoEKW8tJxq2rPEqcUPL3pGoRbGZGmnPv4hByBWwUsjC-W9uiaMsqH4GQo2AEwMMjMgTOmScEE8dkyJjvexCJaEDOnFszxgTzw1MyAJAMBGdD8vqMS93YL6RvuGzz_qxKWhk6nsSczu1SlxmdYYl0-r2p0bndO-noh210YUs6CWg_F3TeFZtVlXYNugtyYnTu8PKwz8n7w3QxfvTmL7On8f3cS4NINp4EaZJAcplmJkkMCowly3QmuBSaywRCaUQiQhQGeMakgczPIiljbZD7hgfn5Gbfu6mrzxZdowrrUsxzXWLVOhVBCAGP4x4M9mBaV87VaNSmtoWuOwVM7UyqX5OqN6kCtTPZp64P9W1SYPaXOajrgds9sLLL1dbWqFyh87zHQW23239VPyzKfmc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71413599</pqid></control><display><type>article</type><title>Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Cippitelli, Marco ; Fionda, Cinzia ; Di Bona, Danilo ; Di Rosa, Francesca ; Lupo, Aldo ; Piccoli, Mario ; Frati, Luigi ; Santoni, Angela</creator><creatorcontrib>Cippitelli, Marco ; Fionda, Cinzia ; Di Bona, Danilo ; Di Rosa, Francesca ; Lupo, Aldo ; Piccoli, Mario ; Frati, Luigi ; Santoni, Angela</creatorcontrib><description>Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and for maintenance of peripheral tolerance. Aberrant expression of Fas and FasL has also been implicated in diseases in which the lymphocyte homeostasis is compromised, and several studies have described the pathogenic functions of Fas and FasL in vivo, particularly in the induction/regulation of organ-specific autoimmune diseases. The 1,25(OH)(2)D(3) is a secosteroid hormone that activates the nuclear receptor vitamin D(3) receptor (VDR), whose immunosuppressive activities have been well studied in different models of autoimmune disease and in experimental organ transplantation. We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-gamma and IL-12 genes by 1,25(OH)(2)D(3) in activated T lymphocytes and macrophages/dendritic cells. In this study, we describe the effect of 1,25(OH)(2)D(3) on the activation of the fasL gene in T lymphocytes. We show that 1,25(OH)(2)D(3) inhibits activation-induced cell death, fasL mRNA expression, and that 1,25(OH)(2)D(3)-activated VDR represses fasL promoter activity by a mechanism dependent on the presence of a functional VDR DNA-binding domain and ligand-dependent transcriptional activation domain (AF-2). Moreover, we identified a minimal region of the promoter containing the transcription start site and a noncanonical c-Myc-binding element, which mediates this repression. These results place FasL as a novel target for the immunoregulatory activities of 1,25(OH)(2)D(3), and confirm the interest for a possible pharmacological use of this molecule and its derivatives.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.168.3.1154</identifier><identifier>PMID: 11801650</identifier><language>eng</language><publisher>United States: Am Assoc Immnol</publisher><subject>Animals ; Cell Death - drug effects ; Cell Death - immunology ; Cholecalciferol - pharmacology ; Cytotoxicity, Immunologic - drug effects ; Cytotoxicity, Immunologic - genetics ; DNA-Binding Proteins - genetics ; DNA-Binding Proteins - physiology ; Down-Regulation - drug effects ; Down-Regulation - genetics ; Down-Regulation - immunology ; Fas Ligand Protein ; Humans ; Hybridomas - cytology ; Hybridomas - drug effects ; Hybridomas - immunology ; Immunosuppressive Agents - pharmacology ; Jurkat Cells ; Lymphocyte Activation - drug effects ; Lymphocyte Activation - genetics ; Membrane Glycoproteins - antagonists & inhibitors ; Membrane Glycoproteins - biosynthesis ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - physiology ; Mice ; Point Mutation ; Promoter Regions, Genetic - drug effects ; Promoter Regions, Genetic - immunology ; Protein Structure, Tertiary - drug effects ; Protein Structure, Tertiary - genetics ; Protein Structure, Tertiary - physiology ; Receptors, Calcitriol - genetics ; Receptors, Calcitriol - physiology ; Regulatory Sequences, Nucleic Acid - drug effects ; Regulatory Sequences, Nucleic Acid - immunology ; Sequence Deletion - immunology ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology ; Tumor Cells, Cultured</subject><ispartof>The Journal of immunology (1950), 2002-02, Vol.168 (3), p.1154-1166</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-818fb3858cdfbbfe6e980dad6586a58b148f6b64e6f15d08f1d2d7889afe52f53</citedby><cites>FETCH-LOGICAL-c378t-818fb3858cdfbbfe6e980dad6586a58b148f6b64e6f15d08f1d2d7889afe52f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11801650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cippitelli, Marco</creatorcontrib><creatorcontrib>Fionda, Cinzia</creatorcontrib><creatorcontrib>Di Bona, Danilo</creatorcontrib><creatorcontrib>Di Rosa, Francesca</creatorcontrib><creatorcontrib>Lupo, Aldo</creatorcontrib><creatorcontrib>Piccoli, Mario</creatorcontrib><creatorcontrib>Frati, Luigi</creatorcontrib><creatorcontrib>Santoni, Angela</creatorcontrib><title>Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and for maintenance of peripheral tolerance. Aberrant expression of Fas and FasL has also been implicated in diseases in which the lymphocyte homeostasis is compromised, and several studies have described the pathogenic functions of Fas and FasL in vivo, particularly in the induction/regulation of organ-specific autoimmune diseases. The 1,25(OH)(2)D(3) is a secosteroid hormone that activates the nuclear receptor vitamin D(3) receptor (VDR), whose immunosuppressive activities have been well studied in different models of autoimmune disease and in experimental organ transplantation. We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-gamma and IL-12 genes by 1,25(OH)(2)D(3) in activated T lymphocytes and macrophages/dendritic cells. In this study, we describe the effect of 1,25(OH)(2)D(3) on the activation of the fasL gene in T lymphocytes. We show that 1,25(OH)(2)D(3) inhibits activation-induced cell death, fasL mRNA expression, and that 1,25(OH)(2)D(3)-activated VDR represses fasL promoter activity by a mechanism dependent on the presence of a functional VDR DNA-binding domain and ligand-dependent transcriptional activation domain (AF-2). Moreover, we identified a minimal region of the promoter containing the transcription start site and a noncanonical c-Myc-binding element, which mediates this repression. These results place FasL as a novel target for the immunoregulatory activities of 1,25(OH)(2)D(3), and confirm the interest for a possible pharmacological use of this molecule and its derivatives.</description><subject>Animals</subject><subject>Cell Death - drug effects</subject><subject>Cell Death - immunology</subject><subject>Cholecalciferol - pharmacology</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Cytotoxicity, Immunologic - genetics</subject><subject>DNA-Binding Proteins - genetics</subject><subject>DNA-Binding Proteins - physiology</subject><subject>Down-Regulation - drug effects</subject><subject>Down-Regulation - genetics</subject><subject>Down-Regulation - immunology</subject><subject>Fas Ligand Protein</subject><subject>Humans</subject><subject>Hybridomas - cytology</subject><subject>Hybridomas - drug effects</subject><subject>Hybridomas - immunology</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Jurkat Cells</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocyte Activation - genetics</subject><subject>Membrane Glycoproteins - antagonists & inhibitors</subject><subject>Membrane Glycoproteins - biosynthesis</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - physiology</subject><subject>Mice</subject><subject>Point Mutation</subject><subject>Promoter Regions, Genetic - drug effects</subject><subject>Promoter Regions, Genetic - immunology</subject><subject>Protein Structure, Tertiary - drug effects</subject><subject>Protein Structure, Tertiary - genetics</subject><subject>Protein Structure, Tertiary - physiology</subject><subject>Receptors, Calcitriol - genetics</subject><subject>Receptors, Calcitriol - physiology</subject><subject>Regulatory Sequences, Nucleic Acid - drug effects</subject><subject>Regulatory Sequences, Nucleic Acid - immunology</subject><subject>Sequence Deletion - immunology</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><subject>Tumor Cells, Cultured</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtOwzAQRS0EouXxBUjIK1ileJLYcZaoLQWpAoEKW8tJxq2rPEqcUPL3pGoRbGZGmnPv4hByBWwUsjC-W9uiaMsqH4GQo2AEwMMjMgTOmScEE8dkyJjvexCJaEDOnFszxgTzw1MyAJAMBGdD8vqMS93YL6RvuGzz_qxKWhk6nsSczu1SlxmdYYl0-r2p0bndO-noh210YUs6CWg_F3TeFZtVlXYNugtyYnTu8PKwz8n7w3QxfvTmL7On8f3cS4NINp4EaZJAcplmJkkMCowly3QmuBSaywRCaUQiQhQGeMakgczPIiljbZD7hgfn5Gbfu6mrzxZdowrrUsxzXWLVOhVBCAGP4x4M9mBaV87VaNSmtoWuOwVM7UyqX5OqN6kCtTPZp64P9W1SYPaXOajrgds9sLLL1dbWqFyh87zHQW23239VPyzKfmc</recordid><startdate>20020201</startdate><enddate>20020201</enddate><creator>Cippitelli, Marco</creator><creator>Fionda, Cinzia</creator><creator>Di Bona, Danilo</creator><creator>Di Rosa, Francesca</creator><creator>Lupo, Aldo</creator><creator>Piccoli, Mario</creator><creator>Frati, Luigi</creator><creator>Santoni, Angela</creator><general>Am Assoc Immnol</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020201</creationdate><title>Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes</title><author>Cippitelli, Marco ; Fionda, Cinzia ; Di Bona, Danilo ; Di Rosa, Francesca ; Lupo, Aldo ; Piccoli, Mario ; Frati, Luigi ; Santoni, Angela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-818fb3858cdfbbfe6e980dad6586a58b148f6b64e6f15d08f1d2d7889afe52f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Cell Death - drug effects</topic><topic>Cell Death - immunology</topic><topic>Cholecalciferol - pharmacology</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Cytotoxicity, Immunologic - genetics</topic><topic>DNA-Binding Proteins - genetics</topic><topic>DNA-Binding Proteins - physiology</topic><topic>Down-Regulation - drug effects</topic><topic>Down-Regulation - genetics</topic><topic>Down-Regulation - immunology</topic><topic>Fas Ligand Protein</topic><topic>Humans</topic><topic>Hybridomas - cytology</topic><topic>Hybridomas - drug effects</topic><topic>Hybridomas - immunology</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Jurkat Cells</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocyte Activation - genetics</topic><topic>Membrane Glycoproteins - antagonists & inhibitors</topic><topic>Membrane Glycoproteins - biosynthesis</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - physiology</topic><topic>Mice</topic><topic>Point Mutation</topic><topic>Promoter Regions, Genetic - drug effects</topic><topic>Promoter Regions, Genetic - immunology</topic><topic>Protein Structure, Tertiary - drug effects</topic><topic>Protein Structure, Tertiary - genetics</topic><topic>Protein Structure, Tertiary - physiology</topic><topic>Receptors, Calcitriol - genetics</topic><topic>Receptors, Calcitriol - physiology</topic><topic>Regulatory Sequences, Nucleic Acid - drug effects</topic><topic>Regulatory Sequences, Nucleic Acid - immunology</topic><topic>Sequence Deletion - immunology</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cippitelli, Marco</creatorcontrib><creatorcontrib>Fionda, Cinzia</creatorcontrib><creatorcontrib>Di Bona, Danilo</creatorcontrib><creatorcontrib>Di Rosa, Francesca</creatorcontrib><creatorcontrib>Lupo, Aldo</creatorcontrib><creatorcontrib>Piccoli, Mario</creatorcontrib><creatorcontrib>Frati, Luigi</creatorcontrib><creatorcontrib>Santoni, Angela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cippitelli, Marco</au><au>Fionda, Cinzia</au><au>Di Bona, Danilo</au><au>Di Rosa, Francesca</au><au>Lupo, Aldo</au><au>Piccoli, Mario</au><au>Frati, Luigi</au><au>Santoni, Angela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2002-02-01</date><risdate>2002</risdate><volume>168</volume><issue>3</issue><spage>1154</spage><epage>1166</epage><pages>1154-1166</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>Fas (APO-1/CD95) and its ligand (FasL/CD95L) are cell surface proteins whose interaction activates apoptosis of Fas-expressing targets. In T lymphocytes, the Fas/FasL system regulates activation-induced cell death, a fundamental mechanism for negative selection of immature T cells in the thymus and for maintenance of peripheral tolerance. Aberrant expression of Fas and FasL has also been implicated in diseases in which the lymphocyte homeostasis is compromised, and several studies have described the pathogenic functions of Fas and FasL in vivo, particularly in the induction/regulation of organ-specific autoimmune diseases. The 1,25(OH)(2)D(3) is a secosteroid hormone that activates the nuclear receptor vitamin D(3) receptor (VDR), whose immunosuppressive activities have been well studied in different models of autoimmune disease and in experimental organ transplantation. We and others have recently described the molecular mechanisms responsible for the negative regulation of the IFN-gamma and IL-12 genes by 1,25(OH)(2)D(3) in activated T lymphocytes and macrophages/dendritic cells. In this study, we describe the effect of 1,25(OH)(2)D(3) on the activation of the fasL gene in T lymphocytes. We show that 1,25(OH)(2)D(3) inhibits activation-induced cell death, fasL mRNA expression, and that 1,25(OH)(2)D(3)-activated VDR represses fasL promoter activity by a mechanism dependent on the presence of a functional VDR DNA-binding domain and ligand-dependent transcriptional activation domain (AF-2). Moreover, we identified a minimal region of the promoter containing the transcription start site and a noncanonical c-Myc-binding element, which mediates this repression. These results place FasL as a novel target for the immunoregulatory activities of 1,25(OH)(2)D(3), and confirm the interest for a possible pharmacological use of this molecule and its derivatives.</abstract><cop>United States</cop><pub>Am Assoc Immnol</pub><pmid>11801650</pmid><doi>10.4049/jimmunol.168.3.1154</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1767 |
ispartof | The Journal of immunology (1950), 2002-02, Vol.168 (3), p.1154-1166 |
issn | 0022-1767 1550-6606 |
language | eng |
recordid | cdi_proquest_miscellaneous_71413599 |
source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Animals Cell Death - drug effects Cell Death - immunology Cholecalciferol - pharmacology Cytotoxicity, Immunologic - drug effects Cytotoxicity, Immunologic - genetics DNA-Binding Proteins - genetics DNA-Binding Proteins - physiology Down-Regulation - drug effects Down-Regulation - genetics Down-Regulation - immunology Fas Ligand Protein Humans Hybridomas - cytology Hybridomas - drug effects Hybridomas - immunology Immunosuppressive Agents - pharmacology Jurkat Cells Lymphocyte Activation - drug effects Lymphocyte Activation - genetics Membrane Glycoproteins - antagonists & inhibitors Membrane Glycoproteins - biosynthesis Membrane Glycoproteins - genetics Membrane Glycoproteins - physiology Mice Point Mutation Promoter Regions, Genetic - drug effects Promoter Regions, Genetic - immunology Protein Structure, Tertiary - drug effects Protein Structure, Tertiary - genetics Protein Structure, Tertiary - physiology Receptors, Calcitriol - genetics Receptors, Calcitriol - physiology Regulatory Sequences, Nucleic Acid - drug effects Regulatory Sequences, Nucleic Acid - immunology Sequence Deletion - immunology T-Lymphocytes - drug effects T-Lymphocytes - immunology Tumor Cells, Cultured |
title | Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A12%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Negative%20Regulation%20of%20CD95%20Ligand%20Gene%20Expression%20by%20Vitamin%20D3%20in%20T%20Lymphocytes&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Cippitelli,%20Marco&rft.date=2002-02-01&rft.volume=168&rft.issue=3&rft.spage=1154&rft.epage=1166&rft.pages=1154-1166&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.168.3.1154&rft_dat=%3Cproquest_cross%3E71413599%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71413599&rft_id=info:pmid/11801650&rfr_iscdi=true |